39 results
6-K
EX-99.2
CLYYF
Celyad Oncology SA
5 Sep 23
Celyad Oncology Reports First Half 2023 Financial
6:12am
on a basis that assumes the Company will continue as a going concern and contemplates the realization of assets and satisfaction of liabilities … will continue as a going concern and contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course
6-K
EX-10.1
CLYYF
Celyad Oncology SA
25 Aug 23
Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders
6:07am
Effect, (iii) any waiver or compromise by the Company of a valuable right or of a material obligation owed to it, (iv) any satisfaction or discharge … of any lien, claim, or encumbrance or payment of any obligation by the Company, except in the ordinary course of business and the satisfaction
6-K
CLYYF
Celyad Oncology SA
25 Aug 23
Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders
6:07am
, 2023 (the “First Closing Date”), subject to the satisfaction of customary closing conditions, and the Second Fortress Private Placement is expected … to close before year end subject to the satisfaction of additional closing conditions including the approval by an extraordinary shareholders meeting
6-K
EX-99.1
CLYYF
Celyad Oncology SA
25 Aug 23
Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders
6:07am
pioneering groundbreaking therapies that hold immense promise for patients in need.”
On or around 4 September 2023, subject to satisfaction of customary
6-K
EX-10.3
CLYYF
Celyad Oncology SA
25 Aug 23
Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders
6:07am
or compromise by the Company of a valuable right or of a material obligation owed to it, (iv) any satisfaction or discharge of any lien, claim … , or encumbrance or payment of any obligation by the Company, except in the ordinary course of business and the satisfaction or discharge of which would
6-K
erug5ytec
5 May 23
Celyad Oncology Announces Intent to
7:21am
6-K
EX-99.1
urqy731 fgg8k6
5 May 23
Celyad Oncology Announces Intent to
7:21am
6-K
EX-99.2
3a99x4a f8r3629zq
5 Aug 22
Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlights
6:11am
6-K
EX-10.1
cpwk8 w03kndxmnp
3 Dec 21
Celyad Oncology Announces $32.5 Million Private Placement with Fortress Investment Group
9:19am
6-K
EX-99.1
ymm9cqwkoho9
3 Dec 21
Celyad Oncology Announces $32.5 Million Private Placement with Fortress Investment Group
9:19am
6-K
EX-99.2
wj7u8lne5kpnwqogynfl
4 Aug 21
Celyad Oncology Reports First Half 2021 Financial Results and Recent Business Highlights
4:01pm
6-K
EX-10.1
7t38n4cw883uj e5
7 Jan 21
Celyad Oncology Announces Equity Purchase Agreement for up to $40 Million with Lincoln Park Capital
7:29am
424B5
hv86d8a8oz9t
7 Jan 21
Prospectus supplement for primary offering
7:28am
6-K
EX-1.1
nkumv99nd3fmbbybet
11 Sep 20
Current report (foreign)
5:17pm
424B5
rb7w4g9bi 2ifjgqj
11 Sep 20
Prospectus supplement for primary offering
5:13pm
F-3
e31l hnzd9ao
28 Aug 20
Shelf registration (foreign)
4:02pm
F-3
EX-4.6
tnlomv
28 Aug 20
Shelf registration (foreign)
4:02pm
F-3
EX-4.7
4fswuj n21qix
28 Aug 20
Shelf registration (foreign)
4:02pm